Stereotactic Body Radiation Therapy (SBRT) for Liver Oligometastases: Outcomes and Safety.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

The aim of this study was to investigate adverse effects, progression free survival (PFS), one-year local control (LC) and one-year overall survival (OS) of patients with liver oligometastases treated with stereotactic body radiotherapy (SBRT), and whether there was a significant difference in these parameters in patients with primary colorectal cancer compared to other tumor localizations.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Acta Med Acad

Title: Acta medica academica

Publisher: Academy of Sciences and Arts of Bosnia and Herzegovina

ISSN (Electronic): 1840-2879

ISSN (Print): 1840-1848

Publication date (Electronic): Dec 2020

Volume: 49

Issue: 3

Affiliations

[1 ] International Medical Centers Banja Luka, Affidea, Center for Radiotherapy, Banja Luka, Bosnia and Herzegovina. dejan.cazic@affidea.com.

[2 ] International Medical Centers Banja Luka, Affidea, Center for Radiotherapy, Banja Luka, Bosnia and Herzegovina; Medical Faculty, University of Banja Luka, Banja Luka, Bosnia and Herzegovina.

Article

Publisher Item ID: ama2006-124.311

DOI: 10.5644/ama2006-124.311

PubMed ID: 33781065

SO-VID: fd807be0-63e0-43fd-94b2-1659a02f9ff8

History

Keywords: SBRT,Liver,Oligometastases

Data availability:

Keywords: SBRT, Liver, Oligometastases

Stereotactic Body Radiation Therapy (SBRT) for Liver Oligometastases: Outcomes and Safety.

Read this article at

Abstract

Related collections

Karger: Oncology

Author and article information

Journal

Affiliations

Article

History

Comments

Comment on this article

Similar content 191

Cited by 1